Compare Dow Inc (DOW) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs TG Therapeutics Inc — how do they compare? Dow Inc trades at $28.46 (market cap $20.65B), while TG Therapeutics Inc trades at $55.11 (market cap $8.16B). The key difference: Dow Inc is far larger — about 2.5× TG Therapeutics Inc's market cap, and Dow Inc pays a 4.9% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dow Inc for 82 Days and TG Therapeutics Inc for 16 Days on average.
| DOW | TGTX | |
|---|---|---|
Market Cap | $20.65B | $8.16B |
Volume | 14,126,943 | 1,735,121 |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $59.06 |
52-Week Low | $20.65 | $26.94 |
Typical Hold Time | 82 Days | 16 Days |
Enterprise Value | $36.34B | $8.37B |
Dividend Yield | 4.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $28.42, up 2.34% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported negative net income of -$2.62B in 2025, though it has beaten EPS estimates in recent quarters. Revenue declined to $39.97B in 2025 from $56.9B in 2022, while cash flow from operations dropped significantly. Analyst consensus is a 'Hold' with a $34.22 price target, indicating potential upside from current levels.
The outlook for DOW is cautious due to profitability challenges and declining revenue, offset by positive earnings surprises and a dividend payment. Key risks include margin pressures and high debt levels, while opportunities lie in cost management and market recovery. Investors should weigh the stock's valuation against its financial health and sector headwinds.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
